Advertisement

The Development of Investigator-Initiated Clinical Trials in Surgical Oncology

Published:November 03, 2022DOI:https://doi.org/10.1016/j.soc.2022.07.003

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Park K.U.
        • Mamounas E.P.
        • Katz M.H.G.
        • et al.
        Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles.
        Ann Surg Oncol. 2020; 27: 2269-2275https://doi.org/10.1245/s10434-020-08472-z
        • Tsai S.
        • Evans D.B.
        Lessons learned from investigator-initiated clinical trials for localized pancreatic cancer.
        J Surg Oncol. 2022; 125: 69-74https://doi.org/10.1002/jso.26756
        • Roland C.L.
        • Grubbs E.G.
        • Katz M.H.G.
        • et al.
        Clinical trials-Designing, implementing, and collaborating.
        J Surg Oncol. 2020; 122: 25-28https://doi.org/10.1002/jso.25889
        • Menezes A.S.
        • Barnes A.
        • Scheer A.S.
        • et al.
        Clinical research in surgical oncology: an analysis of ClinicalTrials.gov.
        Ann Surg Oncol. 2013; 20: 3725-3731https://doi.org/10.1245/s10434-013-3054-y
        • Wong B.O.
        • Perera N.D.
        • Shen J.Z.
        • et al.
        Analysis of Registered Clinical Trials in Surgical Oncology, 2008-2020.
        JAMA Netw Open. 2022; 5: e2145511https://doi.org/10.1001/jamanetworkopen.2021.45511
        • Fisher G.
        • O'Dwyer P.
        Importance of surgeons in cooperative groups: Perspectives from the medical oncologists.
        J Surg Oncol. 2022; 125: 93-94https://doi.org/10.1002/jso.26754
        • Demblowski L.A.
        • Busse B.
        • Santangelo G.
        • et al.
        NIH Funding for Surgeon-Scientists in the US: What Is the Current Status?.
        J Am Coll Surg. 2021; 232: 265-274.e2https://doi.org/10.1016/j.jamcollsurg.2020.12.015
        • Lewit R.A.
        • Black C.M.
        • Camp L.
        • et al.
        Association of Surgeon Representation on NIH Study Sections With Receipt of Funding by Surgeon-scientists.
        Ann Surg. 2021; 273: 1042-1048https://doi.org/10.1097/sla.0000000000004836
        • Fanfan D.
        • Ehrlich H.
        • Elkbuli A.
        The Future of the surgeon-scientist: A Journey Funneled through inspiration, Roadblocks and Resilience.
        Ann Med Surg (Lond). 2021; 62: 65-67https://doi.org/10.1016/j.amsu.2020.12.047
        • Keswani S.G.
        • Moles C.M.
        • Morowitz M.
        • et al.
        The Future of Basic Science in Academic Surgery: Identifying Barriers to Success for Surgeon-scientists.
        Ann Surg. 2017; 265: 1053-1059https://doi.org/10.1097/sla.0000000000002009
        • McLennan S.
        • Nussbaumer-Streit B.
        • Hemkens L.G.
        • et al.
        Barriers and Facilitating Factors for Conducting Systematic Evidence Assessments in Academic Clinical Trials.
        JAMA Netw Open. 2021; 4e2136577https://doi.org/10.1001/jamanetworkopen.2021.36577
        • Feehan A.K.
        • Garcia-Diaz J.
        Investigator Responsibilities in Clinical Research. The Ochsner journal.
        Spring. 2020; 20: 44-49https://doi.org/10.31486/toj.19.0085
        • Unger J.M.
        • Vaidya R.
        • Hershman D.L.
        • et al.
        Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation.
        J Natl Cancer Inst. 2019; 111: 245-255https://doi.org/10.1093/jnci/djy221
        • Unger J.M.
        • Hershman D.L.
        • Till C.
        • et al.
        When Offered to Participate": A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials.
        J Natl Cancer Inst. 2021; 113: 244-257https://doi.org/10.1093/jnci/djaa155
        • Harper M.M.
        • Kim J.
        • Pandalai P.K.
        Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.
        J Clin Med. 2022; : 11https://doi.org/10.3390/jcm11102840
        • Benson A.B.
        • Venook A.P.
        • Al-Hawary M.M.
        • et al.
        Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
        J Natl Compr Canc Netw. 2021; 19: 329-359https://doi.org/10.6004/jnccn.2021.0012
        • Highlights F.D.A.
        of Prescribing Information, ONYVIDE (liposomal irinotecan) for injection.
        Drugs@FDA. 2015; : 1-18
        • Santos A.
        • Zanetta S.
        • Cresteil T.
        • et al.
        Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
        Clin Cancer Res. 2000; 6: 2012-2020
        • Kalra A.V.
        • Kim J.
        • Klinz S.G.
        • et al.
        Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
        Cancer Res. 2014; 74: 7003-7013https://doi.org/10.1158/0008-5472.Can-14-0572
        • Wang-Gillam A.
        • Li C.P.
        • Bodoky G.
        • et al.
        Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
        Lancet. 2016; 387: 545-557https://doi.org/10.1016/s0140-6736(15)00986-1
        • Wöll E.
        • Thaler J.
        • Keil F.
        • et al.
        Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
        Anticancer Res. 2017; 37: 5553-5558https://doi.org/10.21873/anticanres.11987
        • Adiwijaya B.S.
        • Kim J.
        • Lang I.
        • et al.
        Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.
        Clin Pharmacol Ther. 2017; 102: 997-1005https://doi.org/10.1002/cpt.720
        • Frøysnes I.S.
        • Andersson Y.
        • Larsen S.G.
        • et al.
        Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial.
        Ann Surg Oncol. 2017; 24: 1916-1922https://doi.org/10.1245/s10434-017-5814-6
        • Leonard S.C.
        • Lee H.
        • Gaddy D.F.
        • et al.
        Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
        Anticancer Drugs. 2017; 28: 1086-1096https://doi.org/10.1097/cad.0000000000000545
        • Tossey J.C.
        • Reardon J.
        • VanDeusen J.B.
        • et al.
        Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
        Med Oncol. 2019; 36: 87https://doi.org/10.1007/s12032-019-1309-6
        • Hulley S.B.C.S.R.
        • Browner W.S.
        • Grady D.G.
        • et al.
        Designing clinical research.
        4 edition. Lippincott Williams and Wilkins, 2013
        • FDA
        The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective.
        • Cumpston M.S.
        • Webb S.A.
        • Middleton P.
        • et al.
        Understanding implementability in clinical trials: a pragmatic review and concept map.
        Trials. 2021; 22: 232https://doi.org/10.1186/s13063-021-05185-w
        • McCoy C.E.
        Understanding the Use of Composite Endpoints in Clinical Trials.
        West J Emerg Med. 2018; 19: 631-634https://doi.org/10.5811/westjem.2018.4.38383
        • Kelly D.
        • Spreafico A.
        • Siu L.L.
        Increasing operational and scientific efficiency in clinical trials.
        Br J Cancer. 2020; 123: 1207-1208https://doi.org/10.1038/s41416-020-0990-8
        • Snyder R.A.
        • Ahmad S.
        • Katz M.H.G.
        Pancreas cancer trials for early stage disease: Surgeons leading therapeutic cooperative group trials.
        J Surg Oncol. 2022; 125: 75-83https://doi.org/10.1002/jso.26701
        • Lundh A.
        • Lexchin J.
        • Mintzes B.
        • et al.
        Industry sponsorship and research outcome.
        Cochrane Database Syst Rev. 2017; 2Mr000033https://doi.org/10.1002/14651858.MR000033.pub3
        • Blümle A.
        • Wollmann K.
        • Bischoff K.
        • et al.
        Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT).
        BMC Med Res Methodol. 2021; 21: 182https://doi.org/10.1186/s12874-021-01359-x
        • Santamaria-Barria J.A.
        • Stern S.
        • Khader A.
        • et al.
        Changing Trends in Industry Funding for Surgical Oncologists.
        Ann Surg Oncol. 2019; 26: 2327-2335https://doi.org/10.1245/s10434-019-07380-1
        • Herfarth H.H.
        • Jackson S.
        • Schliebe B.G.
        • et al.
        Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers.
        Inflamm Bowel Dis. 2017; 23: 14-22https://doi.org/10.1097/mib.0000000000000907
        • Yurttas C.
        • Hoffmann G.
        • Tolios A.
        • et al.
        Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer.
        J Clin Med. 2018; 7: 567https://doi.org/10.3390/jcm7120567
        • Turaga K.
        • Levine E.
        • Barone R.
        • et al.
        Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States.
        Ann Surg Oncol. 2014; 21: 1501-1505https://doi.org/10.1245/s10434-013-3061-z
        • Somkin C.P.
        • Ackerson L.
        • Husson G.
        • et al.
        Effect of medical oncologists' attitudes on accrual to clinical trials in a community setting.
        J Oncol Pract. 2013; 9: e275-e283https://doi.org/10.1200/jop.2013.001120
        • Mahmud A.
        • Zalay O.
        • Springer A.
        • et al.
        Barriers to participation in clinical trials: a physician survey.
        Curr Oncol. 2018; 25: 119-125https://doi.org/10.3747/co.25.3857
        • Landercasper J.
        • Attai D.
        • Atisha D.
        • et al.
        Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference.
        Ann Surg Oncol. 2015; 22: 3174-3183
        • Grant Y.
        • Al-Khudairi R.
        • St John E.
        • et al.
        Patient-level costs in margin re-excision for breast-conserving surgery.
        Br J Surg. 2019; 106: 384-394
        • Torabi R.
        • Hsu C.-H.
        • Patel P.
        • et al.
        Predictors of margin status after breast-conserving operations in an underscreened population.
        Langenbecks Arch Surg. 2013; 398: 455-462
        • Landercasper J.
        • Bennie B.
        • Ahmad H.
        • et al.
        Opportunities to reduce reoperations and to improve inter-facility profiling after initial breast-conserving surgery for cancer. A report from the NCDB.
        Eur Surg Oncol. 2019; 45: 2026-2036
        • Thiels C.
        • D’Angelica M.
        Hepatic artery infusion pumps.
        Journal of Surgical Oncology. 2020; 1: 70-77